17/02/22

#### BINA CHOWDHURY CENTRAL LIBRARY (GIMT & GIPS)

Total No. of printed pages = 3

Azara, Hatkhowapara Guwahati – 781017

### PY 132701

Roll No. of candidate						
		0	-		-	- 2

2021

# B.Pharm 7th Semester (Repeaters) End-Term Examination

### Pharmacy

## PHARMACEUTICS VI(BIOPHARMACEUTICS AND PHARMACOKINETICS)

(Old Regulation)

Full Marks - 100

Time - Three hours

The figures in the margin indicate full marks for the questions.

Answer question No. 1 and any six from the rest

1. Answer the following (MCQ):

 $(10 \times 1 = 10)$ 

- (i) Type IV dissolution apparatus as per USP is:
  - (a) Paddle type apparatus
- (b) Flow through cell
- (c) Reciprocating cylinder
- (d) Paddle over dsk apparatus
- (ii) Very weak bases (pKa = 5.0) nature drug absorbed in which of the following part in our body?
  - (a) Stomach

(b) Intestine

(c) Colon

- (d) Entire length of GIT
- (iii) The term bioavailability refers to the
  - (a) Relationship between the physical and the chemical properties of a drug
  - (b) Measurement of the rate and extent of drug that reaches the systemic circulation
  - (c) Movement of drug into the body tissues over time.
  - (d) Dissolution of a drug in the GIT.

	(iv)	Whi	ch is the major mechanism for	r abso	rption of drug?
		(a)	Active transport	(b)	Pore transport
		(c)	Passive diffusion	(d)	Facilitate diffusion
	- E =				
	(v)	In f	irst order, t <sub>1/2</sub> is:		
		(a)	1/K	(b)	K
		(c)	0.693/K	(d)	2K+1
	(vi)	Acc	ording to BCS classification, t	ype II	drugs have:
		(a)	High solubility and high per	meabi	lity
		(b)	High solubility and low pern	neabil	ity
		(c)	Low solubility and high perr	neabil	lity
		(d)	Low solubility and low perm	eabili	ty
	(vii)	The	erate of drug dissolution of a t	ablet	can be expressed by the equation:
		(a)	Fick's law	(b)	Henderson Hasselbatch equation
		(c)	Noyes Whitney equation	(d)	Michelis Menten equation
	(viii	) In t	he Plasma level time curve th	e AU	C reflects:
		(a) (b)	The amount of active drug war. The amount of drug which is		reaches the systemic circulation rbed
		(c)	The amount of drug which is	s elim	inated
		(d)	The amount of drug which is	s meta	abolised
	(ix)	Wh	ich of the following tissues ha	s the	maximum capacity to biotransform
		(a)	Brain	(b)	Heart
		(c)	Liver	(d)	Skin
	(x)	Cre	atinine clearance is a measur	emen	t of
		(a)	glomerular filtration rate	(b)	passive renal absorption
		(c)	renal excretion rate	(d)	active renal secretion
2.	(a)		scuss in details on various sorption of a drug.	phy	sicochemical factors influencing G
	(b)	Ex	plain the different mechanism	of dr	ug absorption through GIT. (8
3.	(a)		assify different metabolic path reactions of biotransformation		Explain in details the various Phase (3+6
	(b)		ve a detailed description of kinghs.	netics	of Protein drug binding with suitable

2.

Define the term bioavailability and bioequivalence. What are the objectives (a) of bioavailability study? (2+5)Discuss in details about various methods of determination of bioavailability. (b) Explain with suitable diagram the pharmacokinetic and pharmacodynamic 5. (a) parameters of plasma concentration time curve in details. (8)Write a detail note on Plasma protein binding and tissue drug binding. (b) (7)Define apparent volume of distribution. Explain the factors affecting 6. (a) distribution of drugs. (2 + 5 = 7)Explain in details the various methods of enhancement of bioavailability (b) through enhancement of drug solubility. Write a note on one compartment open model. 7. (a) (5)Discuss in detail about the bioequivalence study protocol. (5) What do you mean by in-vitro in-vivo correlation (IVIVC)? Explain in (c) details. (5)What do you mean by renal failure? Explain in details the dose adjustment 8. in renal failure. (2+7)Give the detail of various factors effecting renal clearance of drugs. (b) (6)9. Write a note on the following:  $(3 \times 5 = 15)$ BCS classification System pH partition hypothesis (b) Blood Brain barrier (BBB) (c)